MedTrace Logo

A Long-Term Follow-up Study of Subjects With Gaucher Disease Who Previously Received AVR-RD-02

NCT04836377 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 4

Last updated 2023-08-29

No results posted yet for this study

Summary

This is a multicenter, multinational long-term follow-up study to assess the long-term safety and durability of effect of AVR-RD-02 treatment in subjects who previously received AVR-RD-02 treatment (single dose administration).

Conditions

  • Type 1 Gaucher Disease

Interventions

OTHER

Safety and efficacy assessments

Safety evaluations, disease-specific assessments, and other assessments to monitor for long-term complications of gene therapy intervention

Sponsors & Collaborators

  • AVROBIO

    lead INDUSTRY

Principal Investigators

  • Milena Veselinovic, MD · AVROBIO

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-06
Primary Completion
2023-08-21
Completion
2023-08-21
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04836377 on ClinicalTrials.gov